Patents by Inventor Christian Leisner

Christian Leisner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250129414
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNF? antagonist, e.g., a TNF? antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNF? antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNF? antagonist, e.g., a TNF? antibody, such as LME636.
    Type: Application
    Filed: October 21, 2024
    Publication date: April 24, 2025
    Inventors: Yunsheng He, Christian Leisner, Michael Wald, Georges Weissgerber
  • Patent number: 12146187
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNF? antagonist, e.g., a TNF? antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNF? antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNF? antagonist, e.g., a TNF? antibody, such as LME636.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: November 19, 2024
    Assignee: Novartis AG
    Inventors: Yunsheng He, Christian Leisner, Michael Wald, Georges Weissgerber
  • Publication number: 20230257455
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: December 21, 2022
    Publication date: August 17, 2023
    Inventors: Leonardo BORRAS, Pankaj GUPTA, Stefan HOERER, Stephanie JUNGMICHEL, Christian LEISNER, Sophia REINDL, Philipp Robert RICHLE, Fabian SCHEIFELE, Anna SOBIERAJ
  • Publication number: 20220259296
    Abstract: Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.
    Type: Application
    Filed: February 11, 2022
    Publication date: August 18, 2022
    Inventors: Leonardo BORRAS, Dominik ESCHER, Stephanie JUNGMICHEL, Christian LEISNER, Philipp Robert RICHLE, Fabian SCHEIFELE
  • Publication number: 20190177407
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNF? antagonist, e.g., a TNF? antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNF? antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNF? antagonist, e.g., a TNF? antibody, such as LME636.
    Type: Application
    Filed: June 19, 2017
    Publication date: June 13, 2019
    Inventors: Yunsheng He, Christian Leisner, Michael Wald, Georges Weissberber